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hepatocellular carcinoma: Shortened duration
does not comprise its efficacyRadiofrequency ablation (RFA) is one of the curative
treatments for very early stage (Barcelona clinic liver
cancer [BCLC] Stage 0) and early stage (BCLC Stage A) of
hepatocellular carcinoma (HCC) [1,2]. RFA has a slightly
lower recurrence-free survival rate for early HCC compared
with surgical resection, but RFA has a similar overall sur-
vival rate as resection [3,4].
The applicability of RFA is enhanced by recent advances
in RFA techniques and instruments. New electrodes with
high-power output to maximize the ablative area are
available, such as perfused electrode, multipolar elec-
trode, and a multiple switching system [5]. No-touch mul-
tibipolar RFA provide a better sustained local tumor control
compared with monopolar RFA [6]. The accurate placement
of an electrode is facilitated by imaging-guided RFA using
imaging fusion of real-time ultrasound images combined
with the established fusion of computed tomography/
magnetic resonance imaging [7,8]. RFA can be also applied
for intermediate- and large-sized HCCs by combination
therapy (such as transarterial chemoembolization plus RFA)
[9]. These recent advances of RFA have expanded the range
of treatments of HCC [10,11]. As a result, the demand for
RFA has significantly increased.
Technical strategies have been developed to maximize
the performance of RFA [12]. However, there is no uni-
versal ablation protocol for the RFA procedure. In this
study, Cheng et al designed a study to investigate this
issue. They used an internally cooled electrode with a 3-
cm uninsulated tip (Cool-tip radiofrequency system; Val-
leylab Inc., Boulder, CO, USA). The standard termination
protocol takes 12 minutes for ablation, whereas the early
termination protocol takes 9 minutes. The authors found
that local tumor control rate (as assessed at Week 4 after
RFA) and tumor progression rate (median follow-up of
23 weeks) were similar between these two groups.
Cheng’s result implies that the recommended procedure
time by the manufacturer may be too long for completehttp://dx.doi.org/10.1016/j.aidm.2016.10.001
2351-9797/Copyrightª 2016, The Gastroenterological Society of Taiwan
for the Study of the Liver. Published by Elsevier Taiwan LLC. This is
creativecommons.org/licenses/by-nc-nd/4.0/).ablation. The procedure time can be shortened without
compromising the local tumor control and tumor progres-
sion. This means that physicians can perform more RFAs
within a certain time and the patients’ waiting time for
treatment can be shortened.
Several drawbacks, however, need to be addressed. This
study is a retrospective study, not a randomized study. The
patient number in this study is small. There is a potential
selection bias in allocating the patients to standard or early
termination protocol. It is to be verified whether the early
termination protocol used in this study is the most optimal
one. The system used is Cool-tip radiofrequency system. It
is unclear whether such conclusions can be generated to
other systems.
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